Suppr超能文献

异烟肼在肺结核气溶胶感染模型中的药代动力学-药效学

Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis.

作者信息

Jayaram Ramesh, Shandil Radha K, Gaonkar Sheshagiri, Kaur Parvinder, Suresh B L, Mahesh B N, Jayashree R, Nandi Vrinda, Bharath Sowmya, Kantharaj E, Balasubramanian V

机构信息

AstraZeneca India Pvt. Ltd., Hebbal, Bangalore 560 024, India.

出版信息

Antimicrob Agents Chemother. 2004 Aug;48(8):2951-7. doi: 10.1128/AAC.48.8.2951-2957.2004.

Abstract

Limited data exist on the pharmacokinetic-pharmacodynamic (PK-PD) parameters of the bactericidal activities of the available antimycobacterial drugs. We report on the PK-PD relationships for isoniazid. Isoniazid exhibited concentration (C)-dependent killing of Mycobacterium tuberculosis H37Rv in vitro, with a maximum reduction of 4 log10 CFU/ml. In these studies, 50% of the maximum effect was achieved at a C/MIC ratio of 0.5, and the maximum effect did not increase with exposure times of up to 21 days. Conversely, isoniazid produced less than a 0.5-log10 CFU/ml reduction in two different intracellular infection models (J774A.1 murine macrophages and whole human blood). In a murine model of aerosol infection, isoniazid therapy for 6 days produced a reduction of 1.4 log10 CFU/lung. Dose fractionation studies demonstrated that the 24-h area under the concentration-time curve/MIC (r2 = 0.83) correlated best with the bactericidal efficacy, followed by the maximum concentration of drug in serum/MIC (r2 = 0.73).

摘要

关于现有抗分枝杆菌药物杀菌活性的药代动力学-药效学(PK-PD)参数的数据有限。我们报告了异烟肼的PK-PD关系。异烟肼在体外对结核分枝杆菌H37Rv表现出浓度(C)依赖性杀菌作用,最大降低幅度为4 log10 CFU/ml。在这些研究中,当C/MIC比值为0.5时达到最大效应的50%,并且在长达21天的暴露时间内最大效应并未增加。相反,在两种不同的细胞内感染模型(J774A.1小鼠巨噬细胞和全血)中,异烟肼导致的CFU/ml降低幅度小于0.5 log10。在气溶胶感染的小鼠模型中,异烟肼治疗6天使肺部CFU降低了1.4 log10。剂量分割研究表明,浓度-时间曲线下24小时面积/MIC(r2 = 0.83)与杀菌效果相关性最佳,其次是血清中药物的最大浓度/MIC(r2 = 0.73)。

相似文献

1
Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis.
Antimicrob Agents Chemother. 2004 Aug;48(8):2951-7. doi: 10.1128/AAC.48.8.2951-2957.2004.
4
Pharmacodynamics and pharmacokinetics of SQ109, a new diamine-based antitubercular drug.
Br J Pharmacol. 2005 Jan;144(1):80-7. doi: 10.1038/sj.bjp.0705984.
5
Pharmacokinetic/pharmacodynamic parameters and the choice of high-dosage rifamycins.
Int J Tuberc Lung Dis. 2012 Sep;16(9):1186-9. doi: 10.5588/ijtld.11.0818. Epub 2012 Jul 12.
7
Design, synthesis, and antimycobacterial property of PEG-bis(INH) conjugates.
Chem Biol Drug Des. 2012 Aug;80(2):245-53. doi: 10.1111/j.1747-0285.2012.01394.x. Epub 2012 May 30.
8
Evaluation of an intracellular pharmacokinetic in vitro infection model as a tool to assess tuberculosis therapy.
Int J Antimicrob Agents. 2007 Feb;29(2):212-6. doi: 10.1016/j.ijantimicag.2006.10.001. Epub 2007 Jan 3.

引用本文的文献

1
Carbamate Prodrugs Restrict Metabolism and Improve the Pharmacokinetics of Isoniazid.
ACS Cent Sci. 2025 Jul 9;11(8):1467-1480. doi: 10.1021/acscentsci.5c00576. eCollection 2025 Aug 27.
3
Optimized Sampling Strategies for Isoniazid in East Asian Pediatric Populations Using Population Pharmacokinetics-Informed Approaches.
Drug Des Devel Ther. 2025 May 1;19:3555-3576. doi: 10.2147/DDDT.S503987. eCollection 2025.
4
Pharmacokinetic Analysis of an Isoniazid Suspension Among Spanish Children Under 6 Years of Age.
Antibiotics (Basel). 2025 Jan 12;14(1):74. doi: 10.3390/antibiotics14010074.
6
Prospectively predicting BPaMZ phase IIb/III trial outcomes using a translational mouse-to-human platform.
Antimicrob Agents Chemother. 2024 Oct 8;68(10):e0061524. doi: 10.1128/aac.00615-24. Epub 2024 Sep 17.
7
Precision Medicine Strategies to Improve Isoniazid Therapy in Patients with Tuberculosis.
Eur J Drug Metab Pharmacokinet. 2024 Sep;49(5):541-557. doi: 10.1007/s13318-024-00910-7. Epub 2024 Aug 17.
9
Model-Informed Precision Dosing of Isoniazid: Parametric Population Pharmacokinetics Model Repository.
Drug Des Devel Ther. 2024 Mar 14;18:801-818. doi: 10.2147/DDDT.S434919. eCollection 2024.
10
Isoniazid and rifampicin exposure during treatment in drug-susceptible TB.
Int J Tuberc Lung Dis. 2023 Oct 1;27(10):772-777. doi: 10.5588/ijtld.22.0698.

本文引用的文献

1
FURTHER STUDIES ON THE TIME/CONCENTRATION RELATIONSHIPS OF ISONIAZID AND TUBERCLE BACILLI IN VITRO.
Am Rev Respir Dis. 1965 Mar;91:440-3. doi: 10.1164/arrd.1965.91.3.440.
3
Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis.
Antimicrob Agents Chemother. 2003 Jul;47(7):2118-24. doi: 10.1128/AAC.47.7.2118-2124.2003.
4
Whole blood bactericidal activity during treatment of pulmonary tuberculosis.
J Infect Dis. 2003 Jan 15;187(2):270-8. doi: 10.1086/346053. Epub 2003 Jan 6.
5
Does the dose matter?
Clin Infect Dis. 2001 Sep 15;33 Suppl 3:S233-7. doi: 10.1086/321854.
6
A whole blood bactericidal assay for tuberculosis.
J Infect Dis. 2001 Apr 15;183(8):1300-3. doi: 10.1086/319679. Epub 2001 Mar 8.
7
Role of individual drugs in the chemotherapy of tuberculosis.
Int J Tuberc Lung Dis. 2000 Sep;4(9):796-806.
8
Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model.
Antimicrob Agents Chemother. 1999 May;43(5):1189-91. doi: 10.1128/AAC.43.5.1189.
9
The early bactericidal activity of isoniazid related to its dose size in pulmonary tuberculosis.
Am J Respir Crit Care Med. 1997 Sep;156(3 Pt 1):895-900. doi: 10.1164/ajrccm.156.3.9609132.
10
Low-dose aerosol infection model for testing drugs for efficacy against Mycobacterium tuberculosis.
Antimicrob Agents Chemother. 1996 Dec;40(12):2809-12. doi: 10.1128/AAC.40.12.2809.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验